Patients must have measurable disease; MRI and/or PET/CT scans need to be performed within  weeks prior to registration
Imaging investigations including CT/MRI of chest/abdomen/pelvis or other scans as necessary to document all sites of disease performed within  days prior to randomization. Patients with either measurable disease or non-measurable evaluable disease are eligible.
Patients must have measurable or non-measurable disease; patients must have a chest/abdominal/pelvis computed tomography (CT) scan (or positron emission tomography [PET]/CT of diagnostic quality, conventional or spiral) prior to registration; if the patient is unable to undergo CT with IV contrast due to allergy or renal insufficiency, a non-contrast CT may be performed; all scans needed for assessment of measurable disease must be performed within  days prior to registration; non-measurable disease must be assessed within  days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form
Patients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within  days prior to sub-study registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within  days prior to sub-study registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration
Patients must have measurable disease per RECIST .; computed tomography (CT) scans or magnetic resonance imaging (MRI)s used to assess measurable disease must have been completed within  days prior to registration; if the only measurable disease is cutaneous or subcutaneous, lesions must be at least  mm in greatest dimension and able to be serially recorded using calipers and photographs; tests used to assess non-measurable disease must have been performed within  days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form
Patients must have measurable disease documented by CT or magnetic resonance imaging (MRI); the CT from a combined PET/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within  days prior to step  registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within  days prior to step  registration; all disease must be assessed and documented on the RECIST . and modified RECIST baseline tumor assessment form
Measurable disease as defined by IWG for PTCL, i.e., at least  measurable disease lesion > . cm in at least one dimension by FDG-PET-CT, MRI, or diagnostic CT
Measurable disease: measurable disease is defined by a main lesion measurable on MRI or computed tomography (CT) images (MRI preferred) with clearly defined margins and >=  mm in one dimension; multifocal disease is allowed as long as one lesion meets criteria for measurable disease and progressive disease
All patients must have measurable disease documented by CT, MRI, or nonmeasurable disease documented by physical exam within  days prior to registration
Histologic or cytologically confirmed diagnosis of uveal melanoma with measurable disease (based on RECIST . criteria) in the liver (by CT, PET/CT or MRI) at the time of screening.
Measurable disease by breast ultrasound and MRI
Measurable disease by CT or MRI
Patients who do not have measurable disease on MRI
At least  measurable lesions as defined per modified RECIST . by CT or MRI performed after the last line of anti-cancer therapy within  days of enrollment
Measurable disease detected by imaging exam (CT or MRI).
Subject has measurable disease defined as a tumor that is measurable in  perpendicular diameters on MRI. For a lesion to be considered measurable, it must be at least twice the slice thickness on MRI (ie, visible on  or more axial slices)
Measurable disease by CT or MRI as per RECIST .. Bone-only disease is not permitted.
Patients with measurable disease and/or non-measurable or no evidence of disease assessed at baseline by CT (or MRI where CT is contraindicated) will be entered in this study.
At least one site of measurable disease on x-ray/CT/MRI scan as defined by RECIST .
Patients must have measurable residual disease, defined as tumor that is measurable in two or three perpendicular diameters on MRI; for a lesion to be considered measurable, it must be at least twice the slice thickness on MRI (i.e visible on more than one slice)
Measurable tumor on MRI or CT scan or X-ray
At least one measurable lesion of the disease on imaging (CT or MRI; RECIST .)
Measurable disease by CT or MRI, as defined by RECIST v.
Baseline staging prior to chemoRT initiation must be obtained. If stage IV, there must be documentation by PET/CT scan, CT scan, or MRI, that the patient has evidence of measurable distant disease per RECIST .. Note: Patients with stage IV disease should have limited but measurable metastatic disease (one or two organs involved e.g., liver and lung) and primary tumor deemed resectable.
Measurable disease on MRI performed within  days prior to registration.
Measurable disease by CT or MRI.
Measurable disease by CT or MRI, but with no single lesion measuring more than . cm
Patients with non-measurable disease <  mm on multiparametric MRI or CT scan will be excluded
Measurable disease: measurable disease is defined by a bidimensionally measurable main lesion on MRI or computed tomography (CT) images (MRI preferred) with clearly defined margins; multifocal disease is allowed
Patients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined PET/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within  days prior to Step  re-registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within  days prior to Step  re-registration; all disease must be assessed and documented on the baseline tumor assessment form; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration
Patients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within  days prior to re-registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within  days prior to re-registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration
Patients must have measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within  days prior to step  re-registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within  days prior to step  re-registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration
Patients must have measurable disease; cutaneous lesions measuring at least  cm will be considered measurable; baseline CT or magnetic resonance imaging (MRI) scans of measurable disease sites must be performed within  weeks of study entry
Patients may have measurable or non-measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI) within  days prior to registration; the CT from a combined positron emission tomography (PET)/CT may be used only if it is of diagnostic quality; laboratory parameters are not acceptable as the only evidence of disease; in order to qualify as measurable, measurable disease must be outside previous radiation field; all disease must be assessed and documented on the Baseline Tumor Assessment Form (Response Evaluation Criteria in Solid Tumors [RECIST] .)
Measurable disease by CT or MRI
A minimum of  measurable lesion by CT or MRI
One or more tumors measurable on CT scan per RECIST ..
Measurable disease on CT or MRI by RECIST ..
Patients must have measurable or non-measurable disease documented by CT, magnetic resonance imaging (MRI) or PET/CT; the CT from a combined PET/CT may be used to document only non-measurable disease unless the scan is of diagnostic quality; measurable disease must be assessed by CT within  days prior to registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within  days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form
Patients may have measurable or non-measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within  days prior to re-treatment registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within  days prior to re-treatment registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to RE-TREATMENT registration
Patients must have metastatic disease that is measurable; computed tomography (CT) scans or magnetic resonance imaging (MRI)s used to assess measurable disease must have been completed within  days prior to registration; CT scans or MRIs used to assess non-measurable disease must have been completed within  days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form
Patients must have measurable metastatic disease; computed tomography (CT) scans or magnetic resonance imaging (MRI)s used to assess measurable disease must have been completed within  days prior to registration; CT scans or MRIs used to assess non-measurable disease must have been completed within  days prior to registration; CT scans or MRIs must be assessed and documented on the Baseline Tumor Assessment Form (Response Evaluation Criteria in Solid Tumors [RECIST] .)
Measurable disease defined as at least one uni-dimensional measurable lesion by CT or MRI according to RECIST .
All subjects must have a radiographic assessment (chest or abdominal/pelvic CT or MRI) within  days prior to registration but do not need to have measurable disease.
Patients must have measurable disease according to the standard RECIST version .; CT scans or magnetic resonance imaging (MRIs) used to assess the measurable disease must have been completed within  days prior to registration
Measurable disease on CT or MRI scan by RECIST criteria (required for Phase b only).
Patients must have measurable or non-measurable disease documented by computed tomography (CT) scan; measurable disease must be assessed within  days prior to registration; non-measurable disease must be assessed within  days prior to registration; the CT from a combined positron emission tomography (PET)/CT must not be used to document measurable disease unless it is of diagnostic quality; all disease must be assessed by RECIST and modified RECIST criteria
Measurable disease by CT or MRI
Measurable disease of at least  cm and otherwise based on RECIST ., assessed from MRI scans by a central radiologist.
At least one site of measurable disease on CT/MRI scans as defined by RECIST .. Baseline imaging must be performed within  days of dosing.
Patients must have measurable or non-measurable disease; all measurable lesions must be assessed (by physical examination, computed tomography [CT], or magnetic resonance imaging [MRI] scan) within  days prior to registration; tests to assess non-measurable disease must be performed within  days prior to registration; all disease must be assessed and documented on the baseline tumor assessment form (Response Evaluation Criteria in Solid Tumors [RECIST] .)
Patients must have measurable disease; all measurable lesions must be assessed (by physical examination, CT, or MRI scan) within  days prior to registration; tests to assess non-measurable disease must be performed within  days prior to registration; patients whose only measurable disease is within a previous radiation therapy port must demonstrate clearly progressive disease (in the opinion of the treating investigator) prior to registration; all disease must be assessed and documented on the baseline tumor assessment form (RECIST .)
At least one measurable lesion on screening CT or MRI
Subjects with metastatic disease limited to bone are ineligible unless at least one lytic lesion with identifiable soft tissue components that can be evaluated by MRI or CT, that is measurable (>=  mm at baseline) and can be followed serially by RECIST v .
Patients must have measurable residual disease, defined as tumor that is measurable in two perpendicular diameters on magnetic resonance imaging (MRI); for a lesion to be considered measurable, it must be at least twice the slice thickness on MRI (i.e. visible on more than one slice)
Other metastatic lesions not previously treated with radiation therapy are allowed providing they are measurable by CT or MRI
Measurable disease by CT or MRI per RECIST . criteria
Cohort Expansion: One or more tumors measurable on CT/MRI scan per RECIST v . (Eisenhauer ; Appendix C).
Patients must have measurable disease as defined in Section . (cutaneous lesions measuring at least  cm will be considered measurable). Baseline CT or MRI scans of measurable disease sites must be performed within  weeks of study entry.
Measurable disease by CT or MRI
Patients must have measurable disease to be treated with proton radiation (minimum tumor dimension at least  mm on CT imaging)
Patients may have measurable or non-measurable disease documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease; measurable disease must be assessed within  days prior to registration per response evaluation criteria in solid tumors (RECIST) version (v).; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non- measurable disease must be assessed within  days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form
Imaging investigations including CT/MRI of chest/abdomen/pelvis or other scans as necessary to document all sites of disease done within  days prior to randomization. Patients with either measurable disease OR non-measurable evaluable disease will be eligible.
Patients must have measurable disease per RECIST documented by computed tomography (CT) or magnetic resonance imaging (MRI); the CT from a combined positron emission tomography (PET)/CT may be used to document only non-measurable disease unless it is of diagnostic quality; measurable disease must be assessed within  days prior to registration; pleural effusions, ascites and laboratory parameters are not acceptable as the only evidence of disease; non-measurable disease must be assessed within  days prior to registration; all disease must be assessed and documented on the Baseline Tumor Assessment Form RECIST .
Have one or more metastatic tumors measurable on CT scan or locally advanced measurable disease that has clearly progressed after prior treatment per RECIST criteria.
At least one tumor lesion measurable by CT or MRI scan (according to RECIST v.)
Measurable tumor by CT or MRI
At least  measurable lesion on CT or MRI
Measurable disease on CT scan
